Ahead of key NASH readout, France's Genfit readies plans for $100M US IPO
France’s Genfit has made good on its promise to list itself in the United States as it gears up for the late-stage readout of its lead experimental drug — elafibranor — in patients with NASH, the untreated fatty liver disease that has ravaged the developed world and sparked a flurry of drug development.
The Lille-based company, which is already listed on Euronext Paris under the symbol $GNFT, disclosed plans to raise about $100 million on Nasdaq under the same ticker, it said in a filing on Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
